

Confirmatory Assignment of Inventor

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the undersigned (the "Assignors")

Anton PEKCEC, Boehringer Ingelheim International GmbH, Global Patents,
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, a citizen of Germany;

Inventor of an invention related to:

"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022

do hereby confirm that all my rights, title and interest in and to the same were assigned, and
transferred, to

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
residing in
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany

to whom assignment has been made of all rights and title to the said invention for the following
territories:

**Algeria, Argentina, Bahrain, Brazil, Canada, Chile, China, Colombia, Costa Rica, Ecuador,
Egypt, Eurasia, Georgia, Guatemala, Honduras, India, Indonesia, Iraq, Jordan, Kuwait,
Lebanon, Libya, Morocco, Mexico, Nigeria, OAPI, Oman, Pakistan, Panama, Peru, Qatar,
Dominican Republic, Saudi Arabia, South Africa, Sri Lanka, Sudan, Syria, Taiwan, Thailand,
Trinidad & Tobago, Tunisia, Uruguay, Venezuela, Viet Nam, Yemen, the United Arab
Emirates and the Patent Office of the Cooperation Council for the Arab States of the Gulf**

aforesaid without any restriction whatever.
Done and signed at: see notarization


Anton PEKCEC

05-12-23
Date



Urkundenrolle UVZ 836 / 2023

UZ 988/2023

Wolfgang Fritzenschaft *Tel. +49 7351 3744-660 *Fax +49 7351 3744-666

Authentication of Signature

I hereby authenticate the foregoing signature of

Mr. Dr. Dr. Anton Pekcec, born 15 November 1978,
with business address at 55216 Ingelheim am Rhein, Binger Strasse 173, Germany
identified by presentation of his identity card,

which was undersigned before me.

Biberach, 12 May 2023

Wolfgang Fritzenschaft
Notary



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2008,

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BIP)

hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BII)

all rights in and to the invention

“RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR”

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022


BIP herewith confirms that BII was entitled to file above patent application in BII's name and BIP gives its full consent to BII to apply for corresponding applications in BII's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

ppa.

ppa.


Dr. Georg FUCHS


Dr. Juergen SEITZ

Managing Directors and Authorized Signatories

Herewith it is confirmed that the above ***PATENT ASSIGNMENT*** has been accepted:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

i.V.

Christiane GRUEN
Managing Director

Sabine GERINGER
Patent Paralegal

Authorized Signatories



Urkundenrolle UVZ 838 / 2023

UZ 990/2023

Wolfgang Fritzenschaft *Tel. +49 7351 3744-660 *Fax +49 7351 3744-666

Authentication of Signature

I hereby authenticate the foregoing signature of

1. Mr. Dr. Jürgen Seitz, born 27 March 1974,
with business address at 55216 Ingelheim am Rhein, Binger Strasse 173, Germany
identified by presentation of his identity card,
2. Mr. Dr. Georg Fuchs, born 14 February 1967,
with business address at 55216 Ingelheim am Rhein, Binger Strasse 173, Germany
personally known

which was undersigned before me.

Biberach, 12 May 2023

Wolfgang Fritzenschaft
Notary



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2008,

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BIP)

hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BII)

all rights in and to the invention

“RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR”

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022

BIP herewith confirms that BII was entitled to file above patent application in BII's name and BIP gives its full consent to BII to apply for corresponding applications in BII's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
ppa. ppa.

Dr. Georg FUCHS Dr. Juergen SEITZ
Managing Directors and Authorized Signatories

Herewith it is confirmed that the above ***PATENT ASSIGNMENT*** has been accepted:


BOEHRINGER INGELHEIM INTERNATIONAL GMBH
ppa. i.V.


Dr. Markus WEYMANN
Managing Director


Sabine GERINGER
Patent Paralegal

Authorized Signatories

Certificate verifying signature



I hereby certify the above signatures of

Dr. Markus **Weymann**,

born 27th day of December 1966,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

Mrs. Sabine **Geringer**,


born 13th day of September 1973,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

personally known,

were duly given in my presence.

Ingelheim am Rhein, the 10th day of May 2023


junior notary Lucas Schäfer

as officially appointed representative of

the notary Prof. Dr. Christopher Keim with his office in Ingelheim am Rhein



Confirmatory Assignment of Inventors

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (the "Assignors")

Matthias BERKEMEYER, Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, a citizen of Germany;
Cornelia WALTHER, Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, a citizen of Germany;

inventor/s of an invention related to:

"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: **June 03, 2022** and **June 08, 2022**

do hereby confirm that all my/our rights, title and interest in and to the same were assigned, and transferred, to

BOEHRINGER INGELHEIM RCV GMBH & CO KG


residing in

Dr. Boehringer-Gasse 5-11, 1121 Wien, Austria


to whom assignment has been made of all rights and title to the said invention for the following territories:

Algeria, Argentina, Bahrain, Brazil, Canada, Chile, China, Colombia, Costa Rica, Ecuador, Egypt, Eurasia, Georgia, Guatemala, Honduras, India, Indonesia, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Mexico, Nigeria, OAPI, Oman, Pakistan, Panama, Peru, Qatar, Dominican Republic, Saudi Arabia, South Africa, Sri Lanka, Sudan, Syria, Taiwan, Thailand, Trinidad & Tobago, Tunisia, Uruguay, Venezuela, Viet Nam, Yemen, the United Arab Emirates and the Patent Office of the Cooperation Council for the Arab States of the Gulf

aforesaid without any restriction whatever.
Done and signed at: see notarization


Matthias BERKEMEYER

26.05.23
Date


Cornelia WALTHER

26.05.23
Date

LEERSEITE

Gebühr in Höhe von € 14,30
gem. § 14 TP 13 GebG idF
BGBl. II 191/2011 entrichtet.

B.R.Zl.: 638/2023/eg

Ich bestätige die Echtheit der -----

- a) am 26.05.2023 (sechszwanzigsten Mai zweitausenddreißig) geleisteten
Unterschrift des Herrn **Doktor Matthias BERKEMEYER**, geboren am 09.01.1968
(neunten Jänner neunzehnhundertachtundsechzig), Binger Strasse 173, 55216
Ingelheim am Rhein, Deutschland, und -----
- b) am 26.05.2023 (sechszwanzigsten Mai zweitausenddreißig) geleisteten
Unterschrift der Frau **Doktor Cornelia WALTHER**, geboren am 05.02.1985 (fünften
Februar neunzehnhundertfünfundachtzig), Binger Strasse 173, 55216 Ingelheim am
Rhein, Deutschland. -----

Weiters bestätige ich, dass die Partei/Parteien erklärt hat/haben, dass sie den Inhalt der
Urkunde kennt/kennen und deren Unterfertigung (Signierung) frei von Zwang erfolgt.
Wien, am 26.05.2023 (sechszwanzigsten Mai zweitausenddreißig). -----

Fee in the amount of € 14,30
paid acc. to § 14 TP 13 GebG
idF BGBl. II 191/2011

Certification Register Number: 638/2023/eg

I herewith certify the genuineness-----

- c) of the signature issued on 26.05.2023 (this twentysixth May two thousand and
twentythree) of Mister **Doktor Matthias BERKEMEYER**, born 09.01.1968 (ninth
January nineteen hundred and sixtyeight), Binger Strasse 173, 55216 Ingelheim am
Rhein, Germany, und -----
- d) of the signature issued on 26.05.2023 (this twentysixth May two thousand and
twentythree) of Misses **Doktor Cornelia WALTHER**, born 05.02.1985 (fifth
February nineteen hundred and eightyfive), Binger Strasse 173, 55216 Ingelheim am
Rhein, Germany. -----

Further, I herewith certify that the above mentioned party/parties declared to me, that
the party/parties know/knows the content of the signed document and that the
party/parties sign/signs without duress. -----

Vienna, this 26.05.2023 (this twentysixth May two thousand and twentythree). -----




MAG. ALEXANDER BARDEAU
SUBSTITUT DES ÖFFENTLICHEN NOTARS
DR. CHRISTOPH VÖLKL
WIEN - ALSERGRUND



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2006,

BOEHRINGER INGELHEIM RCV GMBH & CO KG
Dr. Boehringer-Gasse 5-11, 1121 Wien / AT
(hereunder BI RCV)

hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BII)

all rights in and to the invention


"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022

BI RCV herewith confirms that BII was entitled to file above patent application in BII's name and BI RCV gives its full consent to BII to apply for corresponding applications in BII's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM RCV GmbH & CO KG

ppa.



Dr. Darryl MC CONNELL

i.V.



Dr. Markus WOLFRAM

Managing Directors and Authorized Signatories

Herewith it is confirmed that the above **PATENT ASSIGNMENT** has been accepted:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

i.V.

Christiane GRUEN
Managing Director

Sabine GERINGER
Patent Paralegal

Authorized Signatories

LEERSEITE

Gebühr in Höhe von € 14,30
gem. § 14 TP 13 GebG idF
BGBl. II 191/2011 entrichtet.

B.R.Zl.: 671/2023/eg

Ich bestätige die Echtheit: -----

- a) der Firmazeichnung des Herrn **Doktor Darryl MCCONNELL**, geboren am 21.08.1969 (einundzwanzigsten August neunzehnhundertneunundsechzig), Dr. Boehringer-Gasse 5-11, 1121 Wien, in seiner Eigenschaft als Prokurist. -----
- b) der Unterschrift des Herrn **Doktor Markus WOLFRAM**, geboren am 09.03.1966 (neunten März neunzehnhundertsechundsechzig), Dr. Boehringer-Gasse 5-11, 1121 Wien, in seiner angegebenen Eigenschaft als bevollmächtigter Vertreter -----
- jeweils für die **Boehringer Ingelheim RCV GmbH & Co KG** mit dem Sitz in der politischen Gemeinde Wien und der Geschäftsanschrift Dr. Boehringer-Gasse 5-11, 1121 Wien.-----

Gleichzeitig bestätige ich gemäß § 89a (Paragraf neunundachtzig a) der Notariatsordnung auf Grund der heute im elektronischen Weg vorgenommenen Einsicht in das Firmenbuch, dass Herr Doktor Darryl MCCONNELL am heutigen Tag berechtigt ist, für die unter FN 312077 m eingetragene **Boehringer Ingelheim RCV GmbH & Co KG** gemeinsam mit einem Geschäftsführer oder einem weiteren Gesamtprokuristen rechtsverbindlich zu zeichnen. -----

Weiters bestätige ich, dass die Partei/Parteien erklärt hat/haben, dass sie den Inhalt der Urkunde kennt/kennen und deren Unterfertigung (Signierung) frei von Zwang erfolgt.
Wien, am 01.06.2023 (ersten Juni zweitausenddreißig) -----

Fee in the amount of € 14,30
paid acc. to § 14 TP 13 GebG
idF BGBl. II 191/2011

Certification Register Number: 671/2023/eg

I herewith certify the authenticity of the execution of:-----

- c) the signature of Mister **Doktor Darryl MCCONNELL**, born 21.08.1969 (twentyfirst August nineteenhundred and sixtynine), Dr. Boehringer-Gasse 5-11, 1121 Vienna, in his capacity as managing director.-----
- d) the signature of Mister **Doktor Markus WOLFRAM**, born 09.03.1966 (ninth March nineteenhundred and sixtysix), Dr. Boehringer-Gasse 5-11, 1121 Vienna, in his indicated capacity as authorized person,-----
- each for **Boehringer Ingelheim RCV GmbH & Co KG** having its principal office in the political district of the municipality of Vienna with the business address Dr. Boehringer-Gasse 5-11, 1121 Vienna. -----

Further, after inspection of the "Firmenbuch" (Company Register) by electronic means of today, I herewith certify in compliance with § 89a Notary's Order that Mister Doktor

Darryl MCCONNELL, born 21.08.1969 (twentyfirst August nineteenhundred and sixty-nine), is entitled to sign together with a managing director or another officer for and on behalf of the named company **Boehringer Ingelheim RCV GmbH & Co KG**, registered under number FN 312077 m. -----

Further, I herewith certify that the above mentioned party/parties declared to me, that the party/parties know/knows the content of the signed document and that the party/parties sign/signs without duress. -----

Vienna, this 01.06.2023 (this first of january two thousand and twentythree). -----




DR. CHRISTOPH VÖLKL
ÖFFENTLICHER NOTAR



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2006,

BOEHRINGER INGELHEIM RCV GMBH & CO KG
Dr. Boehringer-Gasse 5-11, 1121 Wien / AT
(hereunder BI RCV)

hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder BII)

all rights in and to the invention

"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022

BI RCV herewith confirms that BII was entitled to file above patent application in BII's name and BI RCV gives its full consent to BII to apply for corresponding applications in BII's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM RCV GmbH & CO KG

ppa.

i.V.

Dr. Darryl MC CONNELL Dr. Markus WOLFRAM


Managing Directors and Authorized Signatories

Herewith it is confirmed that the above **PATENT ASSIGNMENT** has been accepted:


BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

i.V.


Dr. Markus WEYMANN


Managing Director


Sabine GERINGER

Patent Paralegal

Authorized Signatories

Certificate verifying signature



I hereby certify the above signatures of

Dr. Markus **Weymann**,

born 27th day of December 1966,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

Mrs. Sabine **Geringer**,


born 13th day of September 1973,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

personally known,

were duly given in my presence.

Ingelheim am Rhein, the 10th day of May 2023


junior notary Lucas Schäfer

as officially appointed representative of

the notary Prof. Dr. Christopher Keim with his office in Ingelheim am Rhein



Confirmatory Assignment of Inventors

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the undersigned (the "Assignors")

Priyanka GUPTA, c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road,
P.O. Box 368, CT 06877-0368 Ridgefield, United States of America, a citizen of India;
Jon Michael REED, c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road,
P.O. Box 368, CT 06877-0368 Ridgefield, United States of America, a citizen of United States of
America;

Inventors of an invention related to:

"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: **June 03, 2022** and **June 08, 2022**

do hereby confirm that all my/our rights, title and interest in and to the same were assigned, and
transferred, to


BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

residing in
900 Ridgebury Road, 06877 Ridgefield, CT 06877, USA

to whom assignment has been made of all rights and title to the said invention for the following
territories:

**Algeria, Argentina, Bahrain, Brazil, Canada, Chile, China, Colombia, Costa Rica, Ecuador,
Egypt, Eurasia, Georgia, Guatemala, Honduras, India, Indonesia, Iraq, Jordan, Kuwait,
Lebanon, Libya, Morocco, Mexico, Nigeria, OAPI, Oman, Pakistan, Panama, Peru, Qatar,
Dominican Republic, Saudi Arabia, South Africa, Sri Lanka, Sudan, Syria, Taiwan, Thailand,
Trinidad & Tobago, Tunisia, Uruguay, Venezuela, Viet Nam, Yemen, the United Arab
Emirates and the Patent Office of the Cooperation Council for the Arab States of the Gulf**

aforesaid without any restriction whatever.
Done and signed at: see notarization



Priyanka GUPTA

16 May 2023
Date




Jon Michael REED

16 May 2023
Date

County of Fairfield ss. Ridgefield


On this the 16 day of May, 2023 before me, Nancy A. O'Grady, the undersigned officer, personally appeared
(Priyanka GUPTA and Jon Michael REED), known to me (or satisfactorily proven) to be the person(s) whose
name(s) (is or are) subscribed to the within instrument and acknowledged that (he, she or they) executed the
same for the purposes therein contained.

In witness whereof I hereunto set my hand.



Nancy A. O'Grady Notary Public
Date Commission Expires: October 31, 2024

Nancy A. O'Grady
Notary Public, State of Connecticut
My Commission Expires Oct. 31, 2024



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2005,

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
900 Ridgebury Road, 06877 Ridgefield, CT 06877/ USA

and

BOEHRINGER INGELHEIM CORPORATION
900 Ridgebury Road, 06877 Ridgefield, CT 06877/ USA
(hereunder assignors),

which hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Binger Strasse 173, 55216 Ingelheim am Rhein / DE
(hereunder assignee)


all rights in and to the invention

“RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR”

for which first applications were filed in US
Serial Nos.: US 63/348,872 and US 63/350,317
Filing Dates: June 03, 2022 and June 08, 2022


Assignors herewith confirm that assignee was entitled to file above patent application in assignee's name and assignors give their full consent to assignee to apply for corresponding applications in assignee's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.




Paula Wittmayer, Executive Director, Legal IP

BOEHRINGER INGELHEIM CORPORATION



Sheila A. Denton, Senior Vice President and General Counsel



Herewith it is confirmed that the above *PATENT ASSIGNMENT* has been accepted:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

i.V.

Christiane GRUEN

Managing Director

Sabine GERINGER

Patent Paralegal


Authorized Signatories

State of Connecticut

County of Fairfield ss. Ridgefield

On this the 10 day of May, 2023 before me, Nancy A. O'Grady, the undersigned officer, personally appeared Sheila Denton and Paula Wittmayer, known to me to be the person whose name is subscribed to the within instrument and acknowledged that he/she/they executed the same for the purposes therein contained.

In witness whereof I hereunto set my hand.



Nancy A. O'Grady Notary Public

Date Commission Expires: October 31, 2024

Nancy A. O'Grady Notary Public, State of Connecticut My Commission Expires Oct. 31, 2024
--



CONFIRMATION of PATENT ASSIGNMENT

By this instrument and in accordance with the terms of the Agreement between the parties effective as of January 01, 2005,

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

900 Ridgebury Road, 06877 Ridgefield, CT 06877/ USA

and

BOEHRINGER INGELHEIM CORPORATION

900 Ridgebury Road, 06877 Ridgefield, CT 06877/ USA

(hereunder assignors),

which hereby confirm having assigned and transferred to

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Binger Strasse 173, 55216 Ingelheim am Rhein / DE

(hereunder assignee)

all rights in and to the invention

“RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR”

for which first applications were filed in US

Serial Nos.: US 63/348,872 and US 63/350,317

Filing Dates: June 03, 2022 and June 08, 2022

Assignors herewith confirm that assignee was entitled to file above patent application in assignee's name and assignors give their full consent to assignee to apply for corresponding applications in assignee's name in other countries and claiming priority of the said application, including but not limited, under the Paris International Convention.

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.


BOEHRINGER INGELHEIM CORPORATION

Herewith it is confirmed that the above *PATENT ASSIGNMENT* has been accepted:

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

ppa.

i.V.



Dr. Markus WEYMANN

Managing Director


S. Geiger

Sabine GERINGER

Patent Paralegal

Authorized Signatories

Certificate verifying signature



I hereby certify the above signatures of

Dr. Markus **Weymann**,

born 27th day of December 1966,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

Mrs. Sabine **Geringer**,


born 13th day of September 1973,

with business address at 55216 Ingelheim am Rhein, Binger Straße
173,

personally known,

were duly given in my presence.

Ingelheim am Rhein, the 10th day of May 2023


junior notary Lucas Schäfer

as officially appointed representative of

the notary Prof. Dr. Christopher Keim with his office in Ingelheim am Rhein





Confirmatory Assignment of Inventors

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (the "Assignors")

Kai Christoph WOLLERT, Richard-Wagner-Strasse 19, 30177 Hannover, Germany; a citizen of Germany;
Mortimer KORF-KLINGEBIEL, Nesselröder Strasse 14, 37115 Duderstadt, Germany; a citizen of Germany;

Inventor/s of an invention in PCT Nos. PCT/EP2023/064899 dated June 03, 2023 and PCT/EP2023/077649 dated October 05, 2023, entitled:

"RECOMBINANT EXPRESSION OF MYELOID-DERIVED GROWTH FACTOR"

for which first applications were filed in US
Serial Nos.: **US 63/348,872** and **US 63/350,317**
Filing Dates: **June 03, 2022** and **June 08, 2022**

do hereby confirm that all my/our rights, title and interest in and to the same were assigned, and transferred, to


MEDIZINISCHE HOCHSCHULE HANNOVER

residing in
Carl-Neuberg-Straße 1, 30625 Hannover, Germany

to whom assignment has been made of all rights and title to the said invention for the following territories:

Algeria, Argentina, Bahrain, Brazil, Canada, Chile, China, Colombia, Costa Rica, Ecuador, Egypt, Eurasia, Georgia, Guatemala, Honduras, India, Indonesia, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Mexico, Nigeria, OAPI, Oman, Pakistan, Panama, Peru, Qatar, Dominican Republic, Saudi Arabia, South Africa, Sri Lanka, Sudan, Syria, Taiwan, Thailand, Trinidad & Tobago, Tunisia, Uruguay, Venezuela, Viet Nam, Yemen, the United Arab Emirates and the Patent Office of the Cooperation Council for the Arab States of the Gulf


aforesaid without any restriction whatever.
Done and signed at: Hannover



Kai Christoph WOLLERT

4/23/2024

Date



Mortimer KORF-KLINGEBIEL

4/23/2024

Date

UVZ: 388 /2024

Vorstehende, vor mir vollzogene Unterschriften

1.

Herr Dr. Kai Christoph Wollert, geb. am 30.10.1964
wohnhaft Richard-Wagner-Str. 19, 30177 Hannover

2.

Herr Dr. Mortimer Korf-Klingebiel, geb. am 06.09.1967
wohnhaft Am Wachteberg 32, 37115 Duderstadt

beglaubige ich hiermit.

Die Erschienenen wiesen sich aus durch Vorlage ihrer gültigen Bundespersonalausweise.

Die Erschienenen willigen ein, dass ihre persönlichen Daten zur internen Bearbeitung bzw. Abwicklung des heutigen Vorgangs in der Kanzlei des Notars gespeichert bzw. verarbeitet werden. Sie bestätigen, dass ihnen das Informationsblatt gem. Artikel 12 ff. DSGVO zur Verfügung gestellt wurde.

Die vorstehend unterschriebene Erklärung habe ich nach § 15 Abs. 3 GBO auf Eintragungsfähigkeit überprüft.

Meine Frage, ob ich oder einer der mit mir verbundenen Kollegen in der vorliegenden Angelegenheit außerhalb meines Notaramtes tätig war oder ist, verneinten die Beteiligten.

Hannover, den 23. April 2024



(Jan Gebauer)
Notar

A handwritten signature in blue ink, appearing to be "Jan Gebauer", written over the printed name.

1



01-2485

ASSIGNMENT

between **Medizinische Hochschule Hannover**
Carl-Neuberg-Straße 1, 30625 Hannover / DE
- hereinafter referred to as Assignor -

and **Boehringer Ingelheim International GmbH**
Binger Straße 173, 55216 Ingelheim am Rhein / DE
- hereinafter referred to as Assignee -

For good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign, transfer, and convey to Assignee all right, title, and interest that exist today and may exist in the future in and to any and all inventions that are disclosed in any of the patent applications recited below, including the following (collectively, the ***“Transferred Rights”***):

- (a) (i) patent applications filed on behalf of BI and in trust of BI and MHH as set out in the table below:

Patent Application Number	Status
WO/2023/233034	Published on 7.12.2023, pending
AR230101411	Withdrawn
LB12814	Withdrawn
TW112120864	Withdrawn
US 18/328215	Withdrawn
US 63/348872	US Provisional Priority Application filed on 3.06.2022 and automatically lapsed
US 63/350317	US Provisional Priority Application filed on 8.06.2022 and automatically lapsed

- (ii) patent applications filed on behalf of BI and MHH as set out in the table below:


Patent Application Number	Status
PCT/EP2023/077649	pending
AR230103314	pending
LB12956	pending
TW112147469	pending

- (b) all rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on any item in section (a), and under any and all patents which may be granted thereof.
- (c) all reissues, reexaminations, extensions, continuations, continuations-in-part, continuing prosecution applications, requests for continuing examinations, divisions, registrations of any item in section (a) – (b);
- (d) all foreign patents, patent applications, and counterparts relating to any item in section (a) – (c);

Assignor hereby authorizes the respective patent office or governmental agency in each jurisdiction to issue any and all patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon any of the Transferred Rights in the name of Assignee, as the assignee to the entire interest therein.


Assignee accepts the transfer of the Transferred Rights.

ASSIGNOR: Medizinische Hochschule Hannover

By: 
Name*: Prof. Dr. Denise HILFIKER-KLEINER
Title: Präsidentin



Martina SAURIN
Vorstand Wirtschaftsführung
und Administration


Witnessed by:

Name*1: 
Christel Tschernitschek

Date: 10.01.2025

ASSIGNEE: Boehringer Ingelheim International GmbH
ppa.


Dr. Oliver LUTZE
Head of Global Patents

ppa. 
Christiane GRUEN
Head of Patent Administration

Witnessed by:

Name*1: S. Geringer
Sabine GERINGER

Date: January 22, 2025

*) Please type the names of the signatories adding their position within the company.

*1) Please type the name of the witness